Corvus Pharmaceuticals Stock News

Wall Street analysts forecast that Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) will report earnings per share (EPS) of ($0.22) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Corvus Pharmaceuticals earnings, with the lowest EPS estimate coming in at ($0.27) and the highest estimate coming in at ($0.17). Corvus Pharmaceuticals posted []

Equities analysts expect Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) to report earnings per share (EPS) of ($0.22) for the current quarter, Zacks reports. Zero analysts have made estimates for Corvus Pharmaceuticals earnings. The lowest EPS estimate is ($0.27) and the highest is ($0.17). Corvus Pharmaceuticals reported earnings of ($0.35) per share during the same quarter last year, []

Analysts at Jefferies Financial Group began coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS) in a report issued on Wednesday, Price Targets.com reports. The firm set a buy rating and a $8.00 price target on the stock. Jefferies Financial Groups target price indicates a potential upside of 141.69% from the companys current price. Several other equities []

Geode Capital Management LLC grew its stake in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 27.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 189,541 shares of the companys stock after buying an additional 40,707 shares during the period. [] The post Geode Capital Management LLC Boosts Stock Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) appeared first on ETF Daily News .

Ocular Therapeutix (NASDAQ:OCUL) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends. Profitability This table compares Ocular Therapeutix and Corvus Pharmaceuticals net margins, return on equity and []

Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) shares, rose in value on Wednesday, 11/24/21, with the stock price up by 2.74% to the previous days close as strong demand from buyers drove the stock to $3.38. Actively observing the price movement in the last trading, the stock closed the session at $3.29, falling within a range of $3.18 Corvus Pharmaceuticals Inc. (NASDAQ: CRVS): Whats Next In 2021? Read More »

Wall Street analysts expect that Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) will announce ($0.22) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Corvus Pharmaceuticals earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.27). Corvus Pharmaceuticals reported earnings per share of ($0.35) during the same quarter last []

Wall Street analysts expect Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) to post earnings per share of ($0.22) for the current quarter, according to Zacks. Zero analysts have issued estimates for Corvus Pharmaceuticals earnings, with estimates ranging from ($0.27) to ($0.17). Corvus Pharmaceuticals reported earnings per share of ($0.35) during the same quarter last year, which would indicate []

Corvus Pharmaceuticals (NASDAQ:CRVS) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends. Risk & Volatility Corvus Pharmaceuticals has a beta of 0.93, suggesting that its stock price […]

Ocular Therapeutix (NASDAQ:OCUL) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation. Profitability This table compares Ocular Therapeutix and Corvus Pharmaceuticals’ net margins, return on equity and […]

Corvus Pharmaceuticals Inc. (NASDAQ:CRVS)s traded shares stood at 1.18 million during the last session, with the companys beta value hitting 0.90. At the close of trading, the stocks price was $3.42, to imply a decrease of -4.74% or -$0.17 in intraday trading. The CRVS shares 52-week high remains $9.54, putting it -178.95% down since that Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) Has Decreased By -16.59 Percent This Year. Is It A Better Buy Than Others? Read More »

Equities research analysts predict that Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) will announce ($0.22) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Corvus Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.27) and the highest is ($0.17). Corvus Pharmaceuticals reported earnings of ($0.35) per share in the same […]

Related Stocks: ITOS , ALT , CRVS , LIFE , LPTX , TNGX , ASLN , BCTG ,

Biotech penny stocks to watch with upcoming events this week. The post 5 Penny Stocks To Watch For November With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Info